NCT Number: NCT00219622
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
This an initial proof of concept, phase to study to assess the safety and efficacy of tofimilast for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Pfizer Investigational Site, La Plata, Buenos Aires, Argentina
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Moderate-severe COPD (GOLD 2003 definition)
- Smoking history of at least 10 pack-years
Exclusion criteria
- Any significant co-morbid disease, particularly cardiovascular
- Use of any maintenance therapy except short acting bronchodilators
Treatment and study plan
Primary outcomes
-
Change from baseline in FEV1 compared to placebo
Secondary outcomes
-
Change from baseline in other lung function parameters, dyspnea, quality of life compared to placebo
Sponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Official study title
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six Week Study Of The Efficacy And Safety Of Tofimilast Dry Powder For Inhalation In Adults Diagnosed With Chronic Obstructive Pulmonary Disease
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Sep 22, 2005
- Registry last updated
- Nov 7, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
NCT07252908
Chronic Disease, Disease Attributes
Chongqing, Chognqing, China
View Trial DetailsGenerative AI for Medication Counselling and Adherence in Community Pharmacies
NCT07649577
Asthma, Bronchial Diseases
Amman, Jordan
View Trial DetailsA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
NCT06979518
Chronic Disease, Disease Attributes
Cypress, California, United States
View Trial DetailsDetecting Systemic Carbon Dioxide Levels With a Novel Biosensor
NCT06367686
Apnea, Chronic Disease
Tønsberg, Norway
View Trial Details